

Creating & Developing Companies To Improve the Human Condition

Trendlines

Medical • Agtech • Labs

Financial Highlights Q1 2017

11 May 2017

SGX: 42T

OTCQX: TRNLY

Agenda

1. Overview, Todd Dollinger, CEO
2. Financial Highlights – Gabi Heller, CFO
3. Upcoming Events, Judith Kleinman, IR Director

Legal Disclaimer

IMPORTANT NOTICE

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information, or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors, such as known and unknown risks and uncertainties, and assumptions including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statement, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its content may be used without the prior written consent of the Company.

I. Overview



Corporate Highlights Q1 2017

- 7th Annual Company Showcase attended by over 450 investors, analysts, entrepreneurs, and industry leaders
- Official launch of Trendlines Medical Singapore
- Receipt of S$2.2 million grant from SPRING Singapore
- 43 companies in Trendlines portfolio at the end of Q1 2017 (44 with addition of Limaca in Q2 2017)
- Fair value of the Portfolio was US$83.8 million as at 31 March 2017

Key Portfolio Developments in Q1 2017

- Trendlines Labs signs agreement with Singapore General Hospital on product development and clinical trial of its stress urinary incontinence device with funding from the Singapore Israel Industrial Research and Development Foundation (SIIRD)
- Gordian Surgical Ltd. receives first European purchase order; system used by surgeons at leading US hospitals
- S.T. Stent Ltd. completes successful first-in-human pilot study
- CoreBone Ltd. and Headway Ltd. receive Israel Ministry of Health approval to market products in Israel
- InPlant Technologies Ltd. signs collaborative agreement with a MNC to develop advanced crop protection products

II. Financial Highlights




Financial Highlights: Q1 2017

- Total current assets: US$14.6 million (31.12.2016: US$17.3 million)
- Net portfolio value: US$83.8 million (31.12.2016: US$83.7 million)
- Total equity: US$76.7 million (31.12.2016: US$78.2 million)

- Key Financial Ratios
  - Current Assets to Current Liabilities = 2.99
  - Total Assets to Total Liabilities = 4.31

- Total income: US$1.2 million (Q1 2016: US$1.1 million)
- Pretax loss: US$1.4 million (Q1 2016: US$1.5 million)
- Net loss: US$1.6 million (Q1 2016: US$0.8 million)

Key Components of Value (US$ million)



(1) Israeli government loans are non-recourse loans which only come due upon exit events
(2) Deferred taxes are related to unrealized portfolio company valuation profits and are offset and paid only upon realization of cash received upon exits.

III. Upcoming Events



Upcoming Events

MIXiii BIOMED

This year marks our 12th appearance at the annual life sciences conference in Tel Aviv.

23-25 May 2017 | David InterContinental







On 25 May 2017, the last day of Biomed, we will announce the winning company and runners-up from the more than 50 applications.

25 May 2017 | Noon | Israel Export Institute

Creating & Developing Companies To Improve the Human Condition

Trendlines
Medical • Agtech • Labs

+972.72.260.7000 | www.trendlines.com

Todd Dollinger, Chairman & CEO
Steve Rhodes, Chairman & CEO

Judith Kleinman, Director
Investor Relations & Corporate Communications
judith@trendlines.com

11 May 2017